Akari Therapeutics Secures Crucial $5.5M Private Placement, Priced Above Market
AKTX is trading near its 52-week low of $3.015 (5.5% above the low).
Summary
Akari Therapeutics announced a crucial $5.5 million private placement offering, successfully priced at $3.74 per ADS, which is notably above the current market price of $3.18. This financing directly addresses the "going concern" warning issued in the company's May 19th 10-Q, which stated a cash runway only into June 2026. The proceeds are earmarked to advance its lead oncology drug candidate, AKTX-101, towards a first-in-human Phase 1 clinical trial. While the offering includes 1,470,588 ADSs and additional warrants that could lead to significant dilution, the above-market pricing suggests investor confidence. This capital infusion is essential for the company's continued operations and critical drug development milestones. Proceeds will be funded in tranches between May 27th and July 15th, with shareholder approval pending for the warrants.
At the time of this announcement, AKTX was trading at $3.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9M. The 52-week trading range was $3.02 to $56.80. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.